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THE aim of the current study was to investigate the
effect of inhibition of nitric oxide (NO) production
after injury on inflammatory cell accumulation and
fibrosis around digital flexor tendon and synovium.
A standard crush injury was applied to the flexor
tendons of the middle digit of the hindpaw and the
overlying muscle and synovium of female Wistar rats.
Thirty animals received an intraperitoneal injection
of either isotonic saline or N(G)-nitro-l-arginine
methyl ester (L-NAME; 5 mg/kg) immediately follow-
ing the crush injury, and five animals were then
sacrificed at various intervals and the paws processed
for histology. Another group of five animals was
sacrificed after 3 days for nitrite determinations. The
results showed that nitrite production and hence NO
synthase activity is doubled at the acute phase of
tendon wound healing, and we can prevent this by
administering a single dose of L-NAME immediately
after injury. The incidence and severity of fibrocel-
lular adhesions between tendon and synovium was
much more marked in animals treated with L-NAME.
Treatment with L-NAME elicited a chronic inflamma-
tory response characterised by a persistent and
extraordinarily severe accumulation of large num-
bers of inflammatory cells in the subcutaneous
tissues, in muscle and in tendon. These findings
indicate that in the case of injured tendon and
synovium, NO could act to protect the healing tissue
from an uncontrolled inflammatory response.
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Introduction
Despite numerous advances in surgical techniques,
formation of adhesions still remains a major problem
in the repair of tendon injuries. Immediately after
flexor tendon injury and surgical repair, intrinsic
healing by tenocytes and extrinsic healing by inflam-
matory cells from the tendon sheath are both thought
to occur.
1 Therefore, extrinsic adhesions formed
between the tendon and the tendon sheath are part
of the normal healing process.
1 Following injury,
post-trauma fibrous adhesions bind adjacent synovial
tissue to injured tendon, resulting in adhesion
formation and subsequent pain, stiffness and disabil-
ity.
In an attempt to stop peritendinous adhesion
formation, administration of antibodies to transform-
ing growth factor-beta (TGF-b), in the early stages of
wound healing, has proved to be of great benefit.
1,2 It
has been established that TGF-b1 is upregulated after
tendon injury and repair in the tendon /wound
environment.
3 Furthermore, the cytokine TGF-b
plays an important role in wound healing and
fibrosis,
2 and during wound healing the ability to
downregulate such an effector molecule may be as
important as its upregulation in order to avoid excess
fibrosis. Manipulation of the TGF-b1, TGF-b2, and
TGF-b3 isoforms by inhibiting their expression,
activation, or signalling has been reported to greatly
reduce scarring and fibrosis in animal models.
4,5
Interestingly, one of the multitude biological actions
of TGF-b is the inhibition of nitric oxide (NO)
production by macrophages through decreasing the
stability and translation of mRNA for the enzyme
nitric oxide synthase (NOS), as well as increasing the
enzyme degradation.
6,7
Within the past two decades NO, a highly reactive
free radical produced from the amino acid arginine
by the enzyme NOS, has gained much attention as a
potent multifunctional signal molecule with wide-
spread action within and between diverse tissues.
8,9
It has recently been reported that NO regulates
wound healing and that inhibition of NO synthesis
may be directly related to impaired healing of
wounds.
10 Indeed, fibroblasts from inducible nitric
oxide synthase (iNOS) knockout mice are reported to
proliferate more slowly, synthesise less collagen, and
contract fibroblast-populated collagen lattices more
slowly than wild-type fibroblasts.
10 Furthermore,
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157collagen synthesis was restored to normal in fibro-
blasts taken from iNOS knockout mice in response to
NO donors (s-nitroso-N-acetylpenicillamine). Thus,
iNOS deficiency causes significant impairment in
wound healing-related properties of fibroblasts,
which confirms that NO plays an important role in
wound healing.
10,11 On the other hand, it has also
been reported that NO may be an important anti-
fibrotic molecule.
12 Long-term treatment of rats with
N(G)-nitro-l-arginine methyl ester (L-NAME), an iso-
form-non-specific inhibitor of NOS, leads to fibrosis
of the heart suggesting that NO may play a role in
preventing tissue fibrosis.
12 Ferrini et al.
12 reported
that iNOS induction occurs in fibrotic plaque of both
the human and rat Peyronie’s disease and that the NO
derived from iNOS appears to counteract reactive
oxygen species (ROS) formation and collagen de-
position. Because the inhibition of iNOS activity leads
to a decrease in the NO/ROS ratio, thereby favouring
the development of fibrosis, it was proposed that
iNOS induction in this tissue may be a protective
mechanism against fibrosis and abnormal wound
healing.
12
Recently, it has been reported that all three NOS
isoforms are expressed during tendon healing, with
differential expression patterns during the various
phases of tendon healing.
13 In the current study we
hypothesised that NO may play a beneficial role in
the healing of tendon injuries and so we examined
the effects of suppression of NO production on
inflammatory cell accumulation and fibrosis around
injured tendon and synovium. We administered an
inhibitor to NOS, L-NAME, in the early stages of
wound healing, immediately after inflicting a stan-
dard open crush injury of rat digital flexor tendon and
synovium.
Materials and methods
Reagents
Tissue culture reagents were purchased from Gibco
BRL (Life Technologies, Paisley, UK). All other
reagents were purchased from Sigma Chemical Co.
(Poole, Dorset, UK), unless otherwise stated.
Animal model
Female Wistar rats weighing in the range of 250 /300
g were anaesthetised using Halothane. Under tourni-
quet control, a longitudinal incision was made in the
plantar surface of the hindpaw and extended along
the line of the middle digit to expose the synovial
canal. A standard crush injury was applied with
Adson’s forceps along the length of the flexor
tendons of the middle digit of the hindpaw and the
overlying muscle and synovium. The wound was
sutured using a continuous nylon suture. The animals
were allowed to mobilise without restriction follow-
ing the procedure. The animals were then sacrificed
by CO2 asphyxiation followed by cervical dislocation
at various time points following injury.
Control uninjured group
Ten animals were sacrificed, five for histology and
five for nitrite determinations.
Crush injury group
Thirty animals received an intraperitoneal injection of
isotonic saline immediately following crush injury.
Five animals were then sacrificed after 3 days, 2, 3, 4
and 5 weeks, and the paws were then processed for
histology. Another group of five animals was sacri-
ficed after 3 days for nitrite determinations.
Crush injury group treated with L-NAME
Thirty animals received an intraperitoneal injection of
L-NAME (5 mg/kg) immediately following the crush
injury. Five animals were then sacrificed after 3 days,
2, 3, 4 and 5 weeks, and the paws were then
processed for histology. Another group of five
animals was sacrificed after 3 days and 5 weeks for
nitrite determinations.
Preparation of specimens for histology
Tissue was prepared for histological examination by
undertaking a block dissection to include the
wounded skin, subcutaneous tissues, tendon, syno-
vium and muscle, all of which were carefully
dissected from the underlying bones. The dissected
tissues were pinned onto cork to achieve good
alignment of the tendons and were then fixed in
10% neutral buffered formalin and processed for
paraffin embedding. Paraffin sections were prepared
in 5 mm sections and stained with haematoxylin and
eosin dyes by standard procedures.
Tissue immunohistochemistry
Block dissected specimens, treated as already de-
scribed, were embedded in OCT medium (Miles Inc.,
Elkhart, IN, USA) and frozen to  /708C. Longitudinal
sections, 5 mm in thickness, were cut onto slides,
allowed to reach room temperature, and then pro-
cessed for immunohistochemical staining of cells
expressing the macrophage marker ED1.
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macrophages using ED1
The sections were washed in Tris-buffered saline
(TBS), and treated with dilute normal serum for 15
min. The slides were then drained and incubated
with mouse anti-rat macrophage clone ED1 (Serotec,
Oxford, UK) (prepared in TBS and bovine serum
albumin) for 1 h at room temperature. After washing
three times in TBS for 5 min, the slides were treated
with biotin-conjugated secondary antibody for 45
min at room temperature. Subsequent to three further
5 min washes in TBS, the sections were incubated
with alkaline phosphate-conjugated extravidin
(Sigma) at a dilution of 1:1000 for 30 min. The
sections were washed three times in TBS and then
visualised using fast 5-bromo-4-chloro-3 indolyl
phosphate/nitro-blue tetrazolium substrate (Sigma).
Preparation of specimens for nitrite
determinations
Dissected tissue (wounded skin, subcutaneous tis-
sues, tendon, synovium and muscle) was carefully
separated from the underlying bones. The tissue was
minced into small pieces and gently disrupted using a
pestle and mortar. Organ cultures were then rinsed in
saline and maintained in RPMI supplemented with
10% foetal calf serum, 100 mg/ml of penicillin, 100 U/
ml of streptomycin, 2.85 mM glutamine and bicarbo-
nate for a total of 8 days at 378C. The release of NO
was measured as nitrite, a stable byproduct of NO.
Nitrite assay
Fifty microlitres of the culture supernates or tissue
extracts were mixed with an equal volume of Griess
reagent, which consisted of 1% sulfanilamide, 0.1%
N(1-naphthyl)-ethylene diamine dihydrochloride and
2.5% phosphoric acid, and left in the dark for 20 min
at room temperature. A BioRad multiscan microtitre
plate reader was used for the determination of the
absorbance at 540 nm, which is proportional to the
concentration of nitrite in the medium.
Results
Figure 1 shows that in digital flexor tendon/synovium
explants from uninjured rats, the explants released
nitrite under basal conditions and thus showed iNOS
activity. The crush injured group that did not receive
L-NAME were sacrificed at the acute phase of
the inflammatory response (3 days) and explant
cultures from these animals showed a statistically
significant increase in levels of nitrite release, when
compared with explants from control uninjured
animals (pB /0.0001). There is greater than a 100%
increase in NOS activity in crush injured paws.
When L-NAME was administered immediately after
the crush injury and the animals sacrificed at the
acute phase of the inflammatory response, namely
3 days, a marked and statistically significant reduction
in levels of nitrite was observed (pB /0.0001 versus
crush injury without L-NAME) (Fig. 1).
When L-NAME was administered immediately after
the crush injury and the animals sacrificed 5 weeks
after the injury, the explant cultures still showed
a statistically significant reduction in the levels of
nitrite release in comparison with the control unin-
jured group (pB /0.005 versus control uninjured
group). Five weeks after a crush injury, the inflam-
matory response in crush injured paws would settle
almost completely and we would expect the NOS
activity in the crush injured paws to be slightly higher
or very close to the control uninjured group.
Figure 2 shows the histological appearance
of normal uninjured paws, and it can be seen that
tendon and synovium are separated by a clear
synovial canal. Epitenon cells on the tendon surface
and the synovial lining cells are one layer thick and
there are few inflammatory cells in the subsynovial
tissues.
Figures 3 /6 show the histological appearance
of the normal wound healing process and the wound
healing process in rats that had been administered
a single dose of the iNOS inhibitor L-NAME immedi-
ately following injury, at various times (namely, 3
days and 2, 3, 4 and 5 weeks subsequent to
wounding).
FIG. 1. Release of nitrite from explant cultures of digital
ﬂexor tendon and synovium. Explant cultures were taken
from (i) control uninjured rats, (ii) crush injured rats after 3
days, and rats treated with L-NAME immediately after crush
injury and sacriﬁced (iii) 3 days and (iv) 5 weeks post-injury.
Explant cultures were incubated for 3 days at 378C and the
accumulation of nitrite, the stable endproduct of NO, was
measured in the supernatant, as described previously. Error
bars represent standard error of the means. ****pB /0.0001
versus crush injury (no L-NAME);
 pB /0.05 and
  pB /0.005
versus control.
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An intense inflammatory cell infiltration was present
in the subcutaneous and subsynovial tissues in
control injuries (Fig. 3A). The subcutaneous tissues
were edematous and somewhat disorganised, and
were heavily infiltrated by inflammatory cells that
were mainly of monocyte/macrophage lineage.
In addition, scattered mast cells were present in the
subsynovial tissues and often lay in close proximity to
the injured tendon. In some areas the inflammatory
cells accumulated in clusters containing numerous
cells. In addition, moderate numbers of leukocytes
were present in the adventitial spaces between
injured muscle bundles.
In animals treated with a single intraperitoneal
injection of L-NAME, the injured tissues were char-
acterised by edema in the subcutaneous tissues,
which were heavily infiltrated by a population of
mononuclear cells that were larger and that had
larger nuclei than those seen in control injured paws
(Fig. 3B). Mast cells were also present in larger
numbers than in control injured paws. The character-
istic feature that distinguished the paws of animals
treated with L-NAME was the extraordinarily severe
adherence of large numbers of mononuclear cells to
tendon and to muscle (Fig. 3C,D, respectively). These
features were not apparent in any of the control
injured paws.
FIG. 2. Uninjured ﬂexor tendon, synovial sheath and sub-
cutaneous tissue in the rat (  /10, haematoxylin and eosin).
Tendon (right) and synovium (left) are separated by a clear
synovial canal. The normal synovial and subsynovial tissues
contain modest numbers of ﬁbroblasts and inﬂammatory
cells.
FIG. 3. Three days after tendon injury in the rat (  /10, haematoxylin and eosin). (A) Control, no treatment: the subcutaneous
tissue is edematous and is invaded by inﬂammatory cells that are mostly monocytes/macrophages and there are some darkly
staining mast cells in close proximity to the tendon. Reproduced by kind permission from Martin Dunitz Ltd (1997). (B) L-
NAME treatment: edema in the subcutaneous tissue that is heavily inﬁltrated by larger mononuclear cells with larger nuclei
than those in control injuries. Greater numbers of mast cells are also seen. (C) L-NAME treatment: severe adherence of large
numbers of mononuclear cells to tendon. This is not normally seen in control injuries. (D) L-NAME treatment: extraordinarily
severe adherence of large numbers of mononuclear cells to muscle. Not apparent in any of the control injured paws.
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numbers in the subcutaneous tissue is much reduced, although mononuclear cells are still present in the extensive areas
where adhesions have formed. In these areas the synovial space is completely obliterated by adhesion formation. Reproduced
by kind permission from Martin Dunitz Ltd (1997). (B) and (C) L-NAME treatment: inﬂammatory cell accumulation in the
subcutaneous tissue is still severe and persistent, and large numbers of mononuclear cells are present in the areas where
adhesions have formed between the synovium and tendon. The adhesions between tendon and synovium have increased and
matured.
FIG. 5. Four weeks after tendon injury in the L-NAME-treated rat: (A)  /10 and (B)  /40, haematoxylin and eosin. Increased
numbers of inﬂammatory cells in the subcutaneous tissues, in muscle and in tendon. Mononuclear cells are much larger (B)
than at 2 or 3 weeks. There are few areas of clear synovial canal, and the tendon has completely merged with the interstitial
tissues in some areas.
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In both groups, there was an overall reduction in the
degree of inflammatory cell infiltration in the sub-
cutaneous tissues and around the tendon, although
the relative differences between the two groups were
maintained. The mononuclear cell bodies and their
nuclei were smaller and more rounded than those
observed 3 days following injury and the differences
were most marked in the paws of animals treated
with L-NAME. In both groups the tendon had become
adherent to synovium in most injured areas. The
adhesions in the L-NAME-treated animals were more
cellular than in control injuries.
Three weeks
In control injured paws the inflammatory cell infiltra-
tion was much reduced in the subcutaneous tissues,
although mononuclear cells were still present in the
extensive areas where adhesions had formed (Fig.
4A). In contrast, the paws of animals treated with L-
NAME showed a severe and persistent inflammatory
cell accumulation (Fig. 4B,C). Most of these cells
were of moderate size with relatively small nuclei.
Fibrocellular adhesions between tendon and syno-
vium had increased and matured.
Four weeks
While the inflammatory cell infiltrate in control
injured paws continued to decrease, the paws of
animals treated with L-NAME showed increased
numbers of inflammatory cells in the subcutaneous
tissues, in muscle and in tendon (Fig. 5A,B). These
mononuclear cells were now much bigger than they
were at 2 and 3 weeks. In many areas the histological
appearances were similar to those observed 3 days
following injury in L-NAME-treated paws, except for
the absence of edema. Mast cells had once more
begun to accumulate in larger numbers than at
previous time intervals and often lay close to tendon.
There were few areas of clear synovial canal and
further merging of tendon with the interstitial tissues
had occurred.
Five weeks
The inflammatory response in control injured paws
had settled almost completely apart from the pre-
sence of some residual mononuclear cells in the
fibrocellular adhesions. The appearances in the L-
NAME-treated animals were identical to those ob-
served at 4 weeks (Fig. 6A,B). The treatment with L-
NAME had elicited a chronic inflammatory response
characterised by the persistent accumulation of large
macrophages and mast cells. Figure 7A,B confirm that
the inflammatory cell population in histological
sections of control 3-week-injured and L-NAME 4-
week-injured paws consist mainly of macrophage
cells. The sections were labelled with the macro-
phage marker ED1.
Discussion
We first examined the effects of administration of a
single dose of L-NAME, immediately after wounding,
on subsequent NOS activity, measured by the release
of nitrite into the medium, within the injured paw. We
compared the release of nitrite from tendon/syno-
vium explant cultures taken from control rats with
uninjured paws and rats with crush-injured paws
with and without L-NAME treatment. Our results
indicate that nitrite production and hence NOS
activity is doubled at the acute phase of tendon
wound healing, and we can prevent this by admin-
istering a single dose of L-NAME immediately after
injury. In a study of rat wound healing, Albina et al.
14
FIG. 6. Five weeks after tendon injury in the L-NAME-treated rat (  /10, haematoxylin and eosin). Chronic inﬂammatory
response still evident with a persistent accumulation of large macrophages and mast cells. Subcutaneous tissue is inﬁltrated
with large numbers of inﬂammatory cells (A and B). Tendon is completely adherent to synovium (B).
H. Darmani et al.
162 Mediators of Inflammation Vol 13  2004showed that L-arginine (the substrate for the enzyme
NOS) is important for efficient wound healing. They
reported that arginine is metabolised by the NO
pathway during the first 3 days of wound healing,
and later on in the wound healing process arginine
was metabolised by the arginase pathway. They
concluded that the sequence of events can be
explained by the fact that immediately after wound-
ing, NO may provide vasodilatation and microbios-
tasis, which are both important events for efficient
wound healing.
The importance of NO in wound healing is due to
its many anti-inflammatory properties, including re-
duction of platelet aggregation, contribution to anti-
microbial defense mechanisms as well as reducing
proinflammatory cytokine production by en-
dothelium.
9 11 NO also inhibits the expression of P-
selectin and two other endothelial cell adhesion
molecules involved in adherence and transendothe-
lial migration of monocytes and lymphocytes, namely
intracellular adhesion molecule-1 (ICAM-1) and vas-
cular cell adhesion molecule-1 (VCAM-1).
15 When
endogenous NO production was blocked by admin-
istration of L-NAME in the current study, there was
extraordinarily severe adherence of large numbers of
mononuclear cells to tendon and to muscle */
features that were not apparent in any of the control
injured paws. Liu et al.
16 observed that administration
of L-NAME induced a significant augmentation of P-
selectin and ICAM-1 gene expression and polymor-
phonuclear neutrophil (PMN) accumulation in a
model of hepatic ischemia-reperfusion in rats. It
was hypothesised that at sites of inflammation, the
increase in NO production by endothelium, macro-
phages, and vascular smooth muscle cells is the
essential compensatory response for maintaining
organ blood flow and inhibiting PMN adhesion and
platelet aggregation. P-selectin is important in pro-
moting rolling and adherence of leukocytes to the
endothelium. These effects on leukocyte rolling act to
capture leukocytes and bring them into contact with
the endothelium, where they can undergo firm
adhesion, a process regulated by other adhesion
molecules (i.e. ICAM-1 and VCAM-1).
16 Thus, inhibi-
tion of NO production by L-NAME is likely to favour
increased circulating leukocyte activation, adherence
to endothelium and transendothelial migration.
It is difficult to explain why a single systemic dose
of L-NAME administered at the time of injury
produces such long-lasting effects. Perhaps it initiates
a cascade of autocrine and paracrine events that are
not reversed as they would be normally when wound
healing mononuclear cells undergo apoptosis 2 /3
weeks following injury.
17 In this regard, it may be
relevant that NO induces macrophage apoptosis and,
in its absence, macrophages may continue to survive
and thrive.
A parallel situation occurs in relation to systemic
TGF-b administration in animals with impaired
wound healing potential. Beck et al.
18 have shown
that a single intravenous dose of TGF-b administered
24 h prior to cutaneous wounding in diabetic or
corticosteroid-treated rats promotes rapid wound
healing, which does not otherwise take place. They
have suggested that TGF-b somehow primes circulat-
ing leukocytes to continue to express repair cyto-
kines for a prolonged period throughout wound
healing.
Increased interstitial accumulation of inflammatory
cells and the development of fibrosis have been
shown to occur in another experimental model of
injury. Rats given 3 days of angiotensin II treatment
that has been preceded by the chronic administration
of L-NAME for 2 weeks develop interstitial cardiac
fibrosis accompanied by chronic mononuclear cell
infiltration.
19 This is accompanied by increased
FIG. 7. (A) Three weeks after tendon injury in an untreated wound in the rat (  /10, 5-bromo-4-chloro-3 indolyl phosphate/nitro-
blue tetrazolium) showing small numbers of macrophages (labelled with the macrophage marker ED1) in the subcutaneous
tissue. (B) Four weeks after tendon injury in L-NAME-treated rats (  /40, 5-bromo-4-chloro-3 indolyl phosphate/nitro-blue
tetrazolium) showing increased numbers of macrophages (labelled with the macrophage marker ED1) in the subcutaneous
tissue. Macrophages are larger than those in the control injury group.
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60-fold increase in fibronectin mRNA. The adminis-
tration of either angiotensin II or L-NAME alone in
these animals was not sufficient to promote inflam-
matory cell accumulation or fibrosis, and the timing
of L-NAME administration was crucial.
19 A paradigm
may be emerging whereby priming of tissues by
injury may permit L-NAME to induce a chronic
inflammatory state by autocrine and paracrine means.
TGF-b released in response to injury is likely to
participate in this process as it also inhibits the
production of NO. TGF-b promotes adhesion forma-
tion in uninjured and injured peritoneum while
inhibition of TGF-b during the early inflammatory
phase of wound healing greatly reduces adhesion
formation around the tendon. The greatly increased
levels of adhesion of leukocytes to tendon and
muscle and the development of severe peritendinous
adhesions in our study may be indicative of a chronic
imbalance in the expression of TGF-b (which is likely
to be overexpressed) and NO (which is likely to be
underexpressed).
Adhesion formation between the injured mesothe-
lial tissue represents an inflammatory response to
trauma and NO, an endogenous anti-adhesive mole-
cule, may be important in the early stages of repair.
So, if NO production is inhibited immediately after
tendon crush injury, the mechanisms necessary for
efficient repair may be compromised and thus an
inflammatory reaction that is initially acute will fail to
subside and a chronic inflammatory response may
supervene. The inflammatory response itself da-
mages host tissues, and indeed the magnitude of
neutrophil influx into acute inflammatory lesions has
been shown to correlate with the intensity of the
inflammatory response and subsequent tissue in-
jury.
20,21 NO can in fact block PMN infiltration to
protect tissues,
22 and administration of L-NAME
immediately after wounding may tamper with this
beneficial effect. Thus, the ability of blocking PMN
infiltration may be one of the mechanisms by which
this endogenous inflammatory mediator may, under
normal circumstances, protect some tissues from
damage; and in the case of injured tendon and
synovium, NO could act to protect the healing tissue
from an uncontrolled inflammatory response.
Taken together, the importance of NO as a
vasodilator and microbiostatic agent (both important
for efficient wound healing) and its ability to block
PMN infiltration, and thus protect the damaged tissue,
may play a role in the efficient healing and repair of
tendon crush injuries.
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